Impact of COVID-19 on outcomes with teclistamab in the phase 1/2 MajesTEC-1 study in patients with relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Usmani, S.; Bahlis, N. J.; Costa, L.; Manteca, M. V. M.; Nooka, A.; Perrot, A.; Thaman, P.; Qi, K.; Uhlar, C.; Chastain, K.; Doyle, M.; van de Donk, N. |
| Abstract Title: | Impact of COVID-19 on outcomes with teclistamab in the phase 1/2 MajesTEC-1 study in patients with relapsed/refractory multiple myeloma |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S93 |
| Language: | English |
| ACCESSION: | WOS:001325737900152 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)01992-X |
| Notes: | Meeting Abstract: P-089 -- Source: Wos |
